**Core Concept**
Eltrombopag is a small molecule that mimics the action of thrombopoietin, a hormone produced by the liver and kidneys that stimulates the production of platelets in the bone marrow. Thrombopoietin binds to its receptor, c-Mpl, on megakaryocytes, which then proliferate and mature to produce platelets.

**Why the Correct Answer is Right**
Eltrombopag works by binding to c-Mpl, the same receptor that thrombopoietin binds to, thereby activating the signaling pathways that lead to an increase in platelet production. This makes it an analogue of thrombopoietin, which is used to treat thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (CITP) or those undergoing chemotherapy. Eltrombopag's mechanism of action is distinct from erythropoietin, which stimulates red blood cell production, and GMCSF, which stimulates white blood cell production.

**Why Each Wrong Option is Incorrect**
**Option A:** Erythropoietin analogues, such as epoetin alfa, stimulate red blood cell production, not platelet production. Eltrombopag does not have a similar mechanism of action.
**Option B:** Erythropoietin receptor agonists would also stimulate red blood cell production, not platelet production. Eltrombopag's action is specific to thrombopoietin receptors, not erythropoietin receptors.
**Option D:** GMCSF analogues stimulate white blood cell production, not platelet production. Eltrombopag's action is specific to thrombopoietin receptors, not GMCSF receptors.

**Clinical Pearl / High-Yield Fact**
Eltrombopag is the first thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (CITP) and those undergoing chemotherapy. It is essential to differentiate it from erythropoietin analogues, which are used to treat anemia.

**✓ Correct Answer: C. Thrombopoietin analogue**